Respiratory Syncytial Virus Infections: all 302 studies

Page 3 of 4. Open to participants first (48), then studies with results posted, then the rest; newest registration first within each.

• Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 AssessmentCompletedNCT05268939
• A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated PregnancyWithdrawnNCT05229068Phase 3
• Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency RoomTerminatedNCT05105191Not applicable
• Severity of RSV Infections in TwinsCompletedNCT05070975
• Impact of the Covid-19 on Respiratory Syncytial Virus (RSV) EpidemicCompletedNCT04944160
• Infection With Respiratory Syncytial Virus in InfantsStatus unknownNCT04925310
• Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative ChildrenTerminatedNCT04919109Phase 1
• Study of VN-0200 in Japanese Healthy Adults and Elderly SubjectsCompletedNCT04914520Phase 1
• Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsCompletedNCT04871724Phase 1
• A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult ParticipantsCompletedNCT04851977Phase 1
• Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC TestCompletedNCT04782336
• Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy AdultsCompletedNCT04752644Phase 2
• Human Challenge Study to Evaluate the Efficacy of MV-012-968 VaccineCompletedNCT04690335Phase 2
• Safety and Efficacy of BARS13 in the ElderlyCompletedNCT04681833Phase 2
• Infection Watch StudyCompletedNCT04623047
• Respiratory Syncytial Virus Infection May be More Dangerous in NeonateStatus unknownNCT04531735
• Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsCompletedNCT04498741Phase 1
• Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive ChildrenCompletedNCT04444284Phase 1
• Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly VolunteersCompletedNCT04295070Phase 1
• Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing SitesCompletedNCT04288921
• Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSVWithdrawnNCT04267822Phase 2
• A Study of AK0529 in Chinese Infants Hospitalized With RSVCompletedNCT04231968Phase 3
• Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy AdultsCompletedNCT04227210Phase 1
• Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in InfantsStatus unknownNCT04144816
• Pharmacokinetics and Safety of RV521 FormulationsCompletedNCT04065698Phase 1
• RSV Study in Adults 60 to 75 Years of AgeCompletedNCT03919591Not applicable
• Emission Patterns of Respiratory Syncytial VirusTerminatedNCT03909867
• A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult ParticipantsCompletedNCT03782662Phase 1
• Inflammatory Mediators Associated With Infection by Respiratory Syncytial VirusCompletedNCT03757429
• Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsCompletedNCT03755778Phase 1
• Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsCompletedNCT03750383Phase 1
• Anti-viral Effect of PC786 on RSV Infection on HSCT RecipientsTerminatedNCT03715023Phase 2
• Anti-RSV Study in Chinese Patients (ASCENT)TerminatedNCT03699202Phase 2
• RESCEU: Defining the Burden of RSV DiseaseActive, not recruitingNCT03698084
• Music Therapy With Intubated and Sedated Pediatric PatientsCompletedNCT03629145Not applicable
• RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in InfantsStatus unknownNCT03627572
• Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult VolunteersCompletedNCT03624790Phase 1
• RESCEU Study, Defining the Burden of Disease of RSV in Older AdultsStatus unknownNCT03621930
• A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy AdultsCompletedNCT03473002Phase 1
• A Study of EDP-938 in Healthy SubjectsCompletedNCT03384823Phase 1
• A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge StudyCompletedNCT03382431Phase 1/2
• A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) InfectionCompletedNCT03258502Phase 2
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated MothersWithdrawnNCT03191383Phase 2
• Effect of Heliox on RSV BronchiolitisCompletedNCT03171142Phase 3
• Specific Respiratory Infections as Triggers of Acute Medical EventsCompletedNCT02984280
• Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of AgeCompletedNCT02952339Phase 1
• Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of AgeTerminatedNCT02948127Phase 1
• RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.WithdrawnNCT02864628Phase 1
• Idylla IFV-RSV Panel Clinical TestingCompletedNCT02786381
• A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial VirusCompletedNCT02673476Phase 2
• Viral Inhibition in Children for Treatment of RSVCompletedNCT02654171Phase 2
• Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT02601612Phase 1
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT02593851Phase 1
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult ParticipantsCompletedNCT02478333Phase 1
• A Study of AK0529 in Infants Hospitalized With RSVTerminatedNCT02460016Phase 1
• Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV VaccineCompletedNCT02419391Phase 1
• Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.CompletedNCT02387606Phase 2
• A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171CompletedNCT02309320Phase 1/2
• Safety, Tolerability and PK Study of AK0529 in Healthy HumanCompletedNCT02297594Phase 1
• RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.CompletedNCT02247726Phase 2
• Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT02237209Phase 1
• A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176CompletedNCT02231671Phase 1
• A Study of ALS-008176 in Infants Hospitalized With RSVCompletedNCT02202356Phase 1
• Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface ExpressionCompletedNCT02201303Phase 1
• A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge ModelCompletedNCT02094365Phase 2
• Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT02040831Phase 1
• Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT01968083Phase 1
• RSV F Dose-Ranging Study in WomenCompletedNCT01960686Phase 2
• RSV Observational Study 2CompletedNCT01922648
• Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)CompletedNCT01915394
• ALX-0171 Safety Study in Adults With Hyperresponsive AirwaysCompletedNCT01909843Phase 1
• Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersCompletedNCT01906164Phase 1
• Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) VaccinesCompletedNCT01905215Phase 1
• Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and ChildrenCompletedNCT01893554Phase 1
• ALX-0171 Phase I Pharmacokinetic Study in Healthy Male VolunteersCompletedNCT01875926Phase 1
• Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT01852266Phase 1
• RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.CompletedNCT01805921Phase 1
• A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806CompletedNCT01801293Phase 1
• Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)WithdrawnNCT01797419Phase 1
• Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)CompletedNCT01756482Phase 2
• Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of AgeCompletedNCT01754428
• ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male VolunteersCompletedNCT01483911Phase 1
• Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and ChildrenCompletedNCT01459198Phase 1
• A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy VolunteersCompletedNCT01355016Phase 1
• Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle VaccineCompletedNCT01290419Phase 1
• RV568 - Viral Challenge With RSVCompletedNCT01230645Phase 1
• Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot StudyCompletedNCT01090557
• Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)CompletedNCT01065935Phase 2
• Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)CompletedNCT00658086Phase 2
• Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the ElderlyCompletedNCT00609635
• Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian ChildrenCompletedNCT00585481
• Safety Study of Oral BTA9881 to Treat RSV InfectionCompletedNCT00504907Phase 1
• Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial VirusCompletedNCT00496821Phase 2
• Continuous Exhaled Breath Condensate pH in Mechanically Ventilated PatientsStatus unknownNCT00429637
• Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody TherapyCompletedNCT00420966
• Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature InfantsCompletedNCT00384462
• A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCTCompletedNCT00232635Phase 2
• Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524CompletedNCT00192478Phase 1/2
• Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy AdultsCompletedNCT00192465Phase 1
• Study to Evaluate MEDI-534 in Healthy AdultsCompletedNCT00111878

← Respiratory Syncytial Virus Infections overview